Genetic, transcriptomic, and epigenetic studies of HIV-associated neurocognitive disorder

Journal of Acquired Immune Deficiency Syndromes

Volumn 65, Issue 4, 2014, Pages 481-503

  Levine, Andrew J ^a   Panos, Stella E ^a   Horvath, Steve ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HAND; HIV; HIV associated neurocognitive disorder; NeuroAIDS; Weighted gene coexpression network analysis; WGCNA

Indexed keywords

AMPHETAMINE; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; APOLIPOPROTEIN E; BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 6; CATECHOL METHYLTRANSFERASE; CATECHOLAMINE; CELL SURFACE RECEPTOR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CURCUMIN; DOPAMINE TRANSPORTER; GENOMIC DNA; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1; MANNOSE BINDING LECTIN 2; MESSENGER RNA; MICRORNA; MICRORNA 142 5P; MICRORNA 34A; MICROTUBULE ASSOCIATED PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELIN; STROMAL CELL DERIVED FACTOR 1; SYNAPTOPHYSIN; TRANSCRIPTOME; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ASTROCYTE; BASAL GANGLION; BLOOD BRAIN BARRIER; BRAIN CELL; CEREBELLUM; COGNITIVE DEFECT; DNA METHYLATION; EPIGENETICS; FRACTIONAL ANISOTROPY; FRONTAL CORTEX; GENE EXPRESSION; GENE ONTOLOGY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETICS; GENOTYPE; GIANT CELL; HETEROZYGOSITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTONE MODIFICATION; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR DEPRESSION; MICROGLIA; MITOCHONDRIAL GENE; MONOCYTE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TEST; NEUROTOXICITY; NONHUMAN; OLIGODENDROGLIA; PALLOR; PARIETAL CORTEX; PERIPHERAL NEUROPATHY; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SPINAL CORD DISEASE; SYNAPTIC TRANSMISSION; TRANSCRIPTOMICS; UPREGULATION; VERBAL MEMORY; VIRUS LOAD; WHITE MATTER;

AIDS DEMENTIA COMPLEX; EPIGENESIS, GENETIC; HIV INFECTIONS; HUMANS; TRANSCRIPTOME;

EID: 84898714450     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000069     Document Type: Review

References (236)

1. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol. 1986;19:517-524
2. Bornstein RA, Nasrallah HA, Para MF, et al. Neuropsychological performance in symptomatic and asymptomatic HIV infection. AIDS. 1993;7:519-524
3. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69: 1789-1799
4. Gisslen M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: Are we overestimating the real prevalence BMC Infect Dis. 2011;11:356
5. Schretlen DJ, Munro CA, Anthony JC, et al. Examining the range of normal intraindividual variability in neuropsychological test performance. J Int Neuropsychol Soc. 2003;9:864-870
6. Blackstone K, Moore DJ, Franklin DR, et al. Defining neurocognitive impairment in HIV: Deficit scores versus clinical ratings. Clin Neuropsychol. 2012;26:894-908
7. Morgello S, Gelman BB, Kozlowski PB, et al. The National Neuro- AIDS Tissue Consortium: A new paradigm in brain banking with an emphasis on infectious disease. Neuropathol Appl Neurobiol. 2001;27: 326-335
8. Woods SP, Rippeth JD, Frol AB, et al. Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol. 2004;26:759-778
9. Moore DJ, Masliah E, Rippeth JD, et al. Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS. 2006;20:879-887
10. Everall I, Vaida F, Khanlou N, et al. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol. 2009;15:360-370
11. Dunlop O, Goplen AK, Liestol K, et al. HIV dementia and apolipoprotein E. Acta Neurol Scand. 1997;95:315-318
12. Sato-Matsumura KC, Berger J, Hainfellner JA, et al. Development of HIV encephalitis in AIDS and TNF-alpha regulatory elements. J Neuroimmunol. 1998;91:89-92
13. Corder EH, Robertson KR, Lannfelt L, et al. HIV-infected subjects with E4 allele for APOE have excess demential and peripheral neuropathy. Nat Med. 1998;4:1182-1184
14. Boven LA, Van Der Bruggen T, van Asbeck BS, et al. Potential role of CCR5 polymorphism in the development of AIDS dementia complex. FEMS Immunol Med Microbiol. 1999;26:243-247
15. van Rij RP, Portegies P, Hallaby T, et al. Reduced prevalence of the CCR5 delta32 heterozygous genotype in human immunodeficiency virus-infected individuals with AIDS dementia complex. J Infect Dis. 1999;180:854-857
16. Quasney MW, Zhang Q, Sargent S, et al. Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. Ann Neurol. 2001;50:157-162
17. Levine AJ, Achim C, Singer EJ, et al. Establishing a Link Between Host Genotype and HIV-Related Neuropathology-A Novel Approach to Understanding Neuropathogenesis. Kona, Hawaii: International Neuropsychological Society; 2012
18. Gonzalez E, Rovin BH, Sen L, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A 2002;99:13795-13800
19. Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. 2005;4:Article
20. Singh KK, Barroga CF, Hughes MD, et al. Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV- 1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection. J Infect Dis. 2003;188:1461-1472
21. Cutler RG, Haughey NJ, Tammara A, et al. Dysregulation of sphingolipid and sterol metabolism by ApoE4 in HIV dementia. Neurology. 2004;63:626-630
22. Diaz-Arrastia R, Gong Y, Kelly C, et al. Host genetic polymorphisms in human immunodeficiency virus-related neurologic disease. J Neurovirol. 2004;10(suppl 1):67-73
23. Singh KK, Ellis RJ, Marquie-Beck J, et al. CCR2 polymorphisms affect neuropsychological impairment in HIV-1-infected adults. J Neuroimmunol. 2004;157:185-192
24. Horvath S, Dong J. Geometric interpretation of gene coexpression network analysis. PLoS Comput Biol. 2008;4:e1000117
25. Valcour VG, Shikuma C, Shiramizu B, et al. Age, apolipoprotein E4, and the risk of HIV dementia: The Hawaii Aging with HIV Cohort. J Neuroimmunol. 2004;157:197-202
26. Shiramizu B, Lau C, Tamamoto A, et al. Feasibility assessment of cerebrospinal fluid from HIV-1-infected children for HIV proviral DNA and monocyte chemoattractant protein 1 alleles. J Investig Med. 2006;54:468-472
27. Burt TD, Agan BK, Marconi VC, et al. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proc Natl Acad Sci U S A 2008;105:8718-8723
28. Pomara N, Belzer KD, Silva R, et al. The apolipoprotein E epsilon4 allele and memory performance in HIV-1 seropositive subjects: Differences at baseline but not after acute oral lorazepam challenge. Psychopharmacology (Berl). 2008;201:125-135
29. Pemberton LA, Stone E, Price P, et al. The relationship between ApoE, TNFA, IL1a, IL1b and IL12b genes and HIV-1-associated dementia. HIV Med. 2008;9:677-680
30. Shirasaki DI, Greiner ER, Al-Ramahi I, et al. Network organization of the huntingtin proteomic interactome in mammalian brain. Neuron. 2012;75:41-57
31. Levine AJ, Singer EJ, Sinsheimer JS, et al. CCL3 genotype and current depression increase risk of HIV-associated dementia. Neurobehav HIV Med. 2009;1:1-7
32. Bousman CA, Cherner M, Atkinson JH, et al. COMT Val158Met polymorphism, executive dysfunction, and sexual risk behavior in the context of HIV infection and methamphetamine dependence. Interdiscip Perspect Infect Dis. 2010;2010:678648
33. Joska JA, Combrinck M, Valcour VG, et al. Association between apolipoprotein E4 genotype and human immunodeficiency virus-associated dementia in younger adults starting antiretroviral therapy in South Africa. J Neurovirol. 2010;16:377-383
34. Spector SA, Singh KK, Gupta S, et al. APOE epsilon4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIVinfected plasma donors. AIDS. 24:1471-1479
35. Sun B, Abadjian L, Rempel H, et al. Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy-treated subjects with human immunodeficiency virus type 1 infection. J Neurovirol. 2010;16:115-124
36. Andres MA, Feger U, Nath A, et al. APOE epsilon 4 allele and CSF APOE on cognition in HIV-infected subjects. J Neuroimmune Pharmacol. 2011;6:389-398
37. Song L, Langfelder P, Horvath S. Comparison of co-expression measures: Mutual information, correlation, and model based indices. BMC Bioinformatics. 2012;13:328
38. Chang L, Andres M, Sadino J, et al. Impact of apolipoprotein E epsilon4 and HIV on cognition and brain atrophy: Antagonistic pleiotropy and premature brain aging. Neuroimage. 2011;58:1017-1027
39. Gupta S, Bousman CA, Chana G, et al. Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: Preliminary findings. J Neurovirol. 2011
40. Bol SM, Booiman T, van Manen D, et al. Single nucleotide polymorphism in gene encoding transcription factor Prep1 is associated with HIV-1-associated dementia. PLoS One. 2012;7:e30990
41. Brown A, Sacktor N, Marder K, et al. CCL3L1 gene copy number in individuals with and without HIV-associated neurocognitive disorder. Curr Biomark Find. 2012;2012:1-6
42. Levine AJ, Sinsheimer JS, Bilder R, et al. Functional polymorphisms in dopamine-related genes: Effect on neurocognitive functioning in HIV+ adults. J Clin Exp Neuropsychol. 2012;34:78-91
43. Soontornniyomkij V, Moore DJ, Gouaux B, et al. Cerebral betaamyloid deposition predicts HIV-associated neurocognitive disorders in APOE epsilon4 carriers. AIDS. 2012;26:2327-2335
44. Morgan EE, Woods SP, Letendre SL, et al. Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol. 2013;19:150-156
45. Panos SE, Hinkin CH, Singer EJ, et al. Apolipoprotein-E genotype and human immunodeficiency virus-associated neurocognitive disorder: The modulating effects of older age and disease severity. Neurobehavioral HIV Med. 2013;5:11-22
46. Singh KK, Wang Y, Gray KP, et al. Genetic variants in the host restriction factor APOBEC3G are associated with HIV-1-related disease progression and central nervous system impairment in children. J Acquir Immune Defic Syndr. 2013;62:197-203
47. Hoare J, Westgarth-Taylor J, Fouche JP, et al. Relationship between apolipoprotein E4 genotype and white matter integrity in HIV-positive young adults in South Africa. Eur Arch Psychiatry Clin Neurosci. 2013; 263:189-195. doi: 10.1007/s00406-012-0341-8
48. Bol SM, Moerland PD, Limou S, et al. Genome-wide association study identifies single nucleotide polymorphism in DYRK1A associated with replication of HIV-1 in monocyte-derived macrophages. PLoS One. 2011;6:e17190
49. Levine AJ, Service S, Miller EN, et al. Genome-wide association study of neurocognitive impairment and dementia in HIV-infected adults. Am J Med Genet B Neuropsychiatr Genet. 2012
50. Letendre SL, Zheng JC, Kaul M, et al. Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. J Neurovirol. 2011;17:63-69
51. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: A RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophagetropic HIV-1. Science. 1996;272:1955-1958
52. Alkhatib G, Broder CC, Berger EA. Cell type-specific fusion cofactors determine human immunodeficiency virus type 1 tropism for T-cell lines versus primary macrophages. J Virol. 1996;70:5487-5494
53. Lane BR, King SR, Bock PJ, et al. The C-X-C chemokine IP-10 stimulates HIV-1 replication. Virology. 2003;307:122-134
54. Gonzalez E, Dhanda R, Bamshad M, et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: Impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci U S A 2001;98:5199-5204
55. Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science. 2005;307:1434-1440
56. Kaul M, Lipton SA. Experimental and potential future therapeutic approaches for HIV-1 associated dementia targeting receptors for chemokines, glutamate and erythropoietin. Neurotox Res. 2005;8:167-186
57. Weiss JM, Nath A, Major EO, et al. HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. J Immunol. 1999;163:2953-2959
58. Zheng J, Thylin MR, Cotter RL, et al. HIV-1 infected and immune competent mononuclear phagocytes induce quantitative alterations in neuronal dendritic arbor: Relevance for HIV-1-associated dementia. Neurotox Res. 2001;3:443-459
59. Zheng J, Thylin MR, Persidsky Y, et al. HIV-1 infected immune competent mononuclear phagocytes influence the pathways to neuronal demise. Neurotox Res. 2001;3:461-484
60. Levine AJ, Singer EJ, Shapshak P. The role of host genetics in the susceptibility for HIV-associated neurocognitive disorders. AIDS Behav. 2009;13:118-132
61. Mummidi S, Okulicz JF, Wright EJ, et al. Genetic susceptibilities for Neuro AIDS. In: Gendelman HE, Grant I, Everall IP, et al, eds. The Neurology of AIDS. 3rd ed. New York, NY: Oxford University Press; 2012:71-89
62. Kaul M, Ma Q, Medders KE, et al. HIV-1 coreceptors CCR5 and CXCR4 both mediate neuronal cell death but CCR5 paradoxically can also contribute to protection. Cell Death Differ. 2007;14:296-305
63. Liu H, Chao D, Nakayama EE, et al. Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A 1999;96:4581-4585
64. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722-725
65. Eugenin EA, Osiecki K, Lopez L, et al. CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: A potential mechanism of HIV-CNS invasion and Neuro AIDS. J Neurosci. 2006;26:1098-1106
66. Conant K, Garzino-Demo A, Nath A, et al. Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. Proceedings of the National Academy of Sciences of the United States of America, March 17, 1998;95(6): 3117-3121
67. Kelder W, McArthur JC, Nance-Sproson T, et al. Beta-chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol. 1998;44:831-835
68. Lehmann MH, Masanetz S, Kramer S, et al. HIV-1 Nef upregulates CCL2/MCP-1 expression in astrocytes in a myristoylation- and calmodulin-dependent manner. J Cell Sci. 2006;119(pt 21):4520-4530
69. McDermott DH, Yang Q, Kathiresan S, et al. CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study. Circulation. 2005;112:1113-1120
70. Letendre S, Marquie-Beck J, Singh KK, et al. The monocyte chemotactic protein-1 -2578G allele is associated with elevated MCP-1 concentrations in cerebrospinal fluid. J Neuroimmunol. 2004;157:193-196
71. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science. 1997;277:959-965
72. Schmidtmayerova H, Nottet HS, Nuovo G, et al. Human immunodeficiency virus type 1 infection alters chemokine beta peptide expression in human monocytes: Implications for recruitment of leukocytes into brain and lymph nodes. Proceedings of the National Academy of Sciences of the United States of America. January 23, 1996;93(2):700-704
73. Modi WS, Lautenberger J, An P, et al. Genetic variation in the CCL18- CCL3-CCL4 chemokine gene cluster influences HIV Type 1 transmission and AIDS disease progression. Am J Hum Genet. 2006;79:120-128
74. Wesselingh SL, Takahashi K, Glass JD, et al. Cellular localization of tumor necrosis factor mRNA in neurological tissue from HIV-infected patients by combined reverse transcriptase/polymerase chain reaction in situ hybridization and immunohistochemistry. J Neuroimmunol. 1997; 74:1-8
75. Yeh MW, Kaul M, Zheng J, et al. Cytokine-stimulated, but not HIVinfected, human monocyte-derived macrophages produce neurotoxic levels of l -cysteine. J Immunol. 2000;164:4265-4270
76. Wesselingh SL, Power C, Glass JD, et al. Intracerebral cytokine messenger RNA expression in acquired immunodeficiency syndrome dementia. Ann Neurol. 1993;33:576-582
77. Chao CC, Hu S. Tumor necrosis factor-alpha potentiates glutamate neurotoxicity in human fetal brain cell cultures. Dev Neurosci. 1994; 16:172-179
78. Benos DJ, McPherson S, Hahn BH, et al. Cytokines and HIV envelope glycoprotein gp120 stimulate Na+/H+ exchange in astrocytes. J Biol Chem. 1994;269:13811-13816
79. Selmaj K, Raine CS. Tumor necrosis factor mediates myelin damage in organotypic cultures of nervous tissue. Ann N Y Acad Sci. 1988;540: 568-570
80. Gelbard HA, Nottet HS, Swindells S, et al. Platelet-activating factor: A candidate human immunodeficiency virus type 1-induced neurotoxin. J Virol. 1994;68:4628-4635
81. Brabers NA, Nottet HS. Role of the pro-inflammatory cytokines TNFalpha and IL-1beta in HIV-associated dementia. Eur J Clin Invest. 2006; 36:447-458
82. Agace WW, Amara A, Roberts AI, et al. Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation. Curr Biol. 2000;10:325-328
83. Asensio VC, Campbell IL. Chemokines in the CNS: Plurifunctional mediators in diverse states. Trends Neurosci. 1999;22:504-512
84. Zheng J, Thylin MR, Ghorpade A, et al. Intracellular CXCR4 signaling, neuronal apoptosis and neuropathogenic mechanisms of HIV-1- associated dementia. J Neuroimmunol. 1999;98:185-200
85. Kaul M, Lipton SA. Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci U S A 1999;96: 8212-8216
86. Kaul M, Zheng J, Okamoto S, et al. HIV-1 infection and AIDS: Consequences for the central nervous system. Cell Death Differ. 2005;12 (suppl 1):878-892
87. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City cohort (SFCC). Science. 1998;279:389-393
88. Corder EH, Galeazzi L, Franceschi C, et al. Differential course of HIV-1 infection and apolipoprotein E polymorphism. Cent Eur J Med. 2007;2:404-416
89. Vitek MP, Brown CM, Colton CA. APOE genotype-specific differences in the innate immune response. Neurobiol Aging. 2009;30:1350-1360
90. Valcour VG, Shiramizu B, Shikuma C. Frequency of apolipoprotein E4 among older compared with younger HIV patients: Support for detrimental effect of E4 on survival. Proc Natl Acad Sci U S A 2008;105: E66
91. Fraser IP, Koziel H, Ezekowitz RA. The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity. Semin Immunol. 1998; 10:363-372
92. Garred P, Madsen HO, Balslev U, et al. Susceptibility to HIV infection and progression of AIDS in relation to variant alleles of mannosebinding lectin. Lancet. 1997;349:236-240
93. Singh KK, Lieser A, Ruan PK, et al. An age-dependent association of mannose-binding lectin-2 genetic variants on HIV-1-related disease in children. J Allergy Clin Immunol. 2008;122:173-180. 180 e171-e172
94. Singh KK, Nathamu S, Adame A, et al. Expression of mannose binding lectin in HIV-1-infected brain: Implications for HIV-related neuronal damage and neuro AIDS. Neurobehav HIV Med. 2011;3:41-52
95. Lachman HM, Papolos DF, Saito T, et al. Human catechol-Omethyltransferase pharmacogenetics: Description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6:243-250
96. Bilder RM, Volavka J, Lachman HM, et al. The catechol-Omethyltransferase polymorphism: Relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology. 2004;29:1943-1961
97. Bilder RM, Volavka J, Czobor P, et al. Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry. 2002;52:701-707
98. Egan MF, Goldberg TE, Kolachana BS, et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A 2001;98:6917-6922
99. Nolan KA, Bilder RM, Lachman HM, et al. Catechol O-methyltransferase Val158Met polymorphism in schizophrenia: Differential effects of Val and Met alleles on cognitive stability and flexibility. Am J Psychiatry. 2004;161:359-361
100. Rosa A, Peralta V, Cuesta MJ, et al. New evidence of association between COMT gene and prefrontal neurocognitive function in healthy individuals from sibling pairs discordant for psychosis. Am J Psychiatry. 2004;161:1110-1112
101. Malhotra AK, Kestler LJ, Mazzanti C, et al. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry. 2002;159:652-654
102. Goldberg TE, Egan MF, Gscheidle T, et al. Executive subprocesses in working memory: Relationship to catechol-O-methyltransferase Val158- Met genotype and schizophrenia. Arch Gen Psychiatry. 2003;60:889-896
103. Mattay VS, Goldberg TE, Fera F, et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci U S A 2003;100:6186-6191
104. Hsieh PC, Yeh TL, Lee IH, et al. Correlation between errors on the Wisconsin Card Sorting Test and the availability of striatal dopamine transporters in healthy volunteers. J Psychiatry Neurosci. 35:90-94
105. Mozley LH, Gur RC, Mozley PD, et al. Striatal dopamine transporters and cognitive functioning in healthy men and women. Am J Psychiatry. 2001;158:1492-1499
106. Wang GJ, Chang L, Volkow ND, et al. Decreased brain dopaminergic transporters in HIV-associated dementia patients. Brain. 2004;127(pt 11):2452-2458
107. Chang L, Wang GJ, Volkow ND, et al. Decreased brain dopamine transporters are related to cognitive deficits in HIV patients with or without cocaine abuse. Neuroimage. 2008;42:869-878
108. Prata DP, Mechelli A, Fu CH, et al. Epistasis between the DAT 3́ UTR VNTR and the COMT Val158Met SNP on cortical function in healthy subjects and patients with schizophrenia. Proc Natl Acad Sci U S A 2009;106:13600-13605
109. Bertolino A, Blasi G, Latorre V, et al. Additive effects of genetic variation in dopamine regulating genes on working memory cortical activity in human brain. J Neurosci. 2006;26:3918-3922
110. VanNess SH, Owens MJ, Kilts CD. The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet. 2005;6:55
111. Guillin O, Diaz J, Carroll P, et al. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature. 2001;411:86-89
112. Mossner R, Daniel S, Albert D, et al. Serotonin transporter function is modulated by brain-derived neurotrophic factor (BDNF) but not nerve growth factor (NGF). Neurochem Int. 2000;36:197-202
113. Nosheny RL, Mocchetti I, Bachis A. Brain-derived neurotrophic factor as a prototype neuroprotective factor against HIV-1-associated neuronal degeneration. Neurotox Res. 2005;8:187-198
114. Nosheny RL, Ahmed F, Yakovlev A, et al. Brain-derived neurotrophic factor prevents the nigrostriatal degeneration induced by human immunodeficiency virus-1 glycoprotein 120 in vivo. Eur J Neurosci. 2007;25: 2275-2284
115. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell. 2003;112:257-269
116. Pezawas L, Verchinski BA, Mattay VS, et al. The brain-derived neurotrophic factor val66met polymorphism and variation in human cortical morphology. J Neurosci. 2004;24:10099-10102
117. Mocchetti I, Nosheny RL, Tanda G, et al. Brain-derived neurotrophic factor prevents human immunodeficiency virus type 1 protein gp120 neurotoxicity in the rat nigrostriatal system. Ann N Y Acad Sci. 2007; 1122:144-154
118. Kumar AM, Ownby RL, Waldrop-Valverde D, et al. Human immunodeficiency virus infection in the CNS and decreased dopamine availability: Relationship with neuropsychological performance. J Neurovirol. 2011;17:26-40
119. Gelman BB, Lisinicchia JG, Chen T, et al. Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis. J Neuroimmune Pharmacol. 2012;7: 686-700
120. Gelman BB, Spencer JA, Holzer CE 3rd, et al. Abnormal striatal dopaminergic synapses in National NeuroAIDS Tissue Consortium subjects with HIV encephalitis. J Neuroimmune Pharmacol. 2006;1:410-420
121. Kumar AM, Fernandez J, Singer EJ, et al. Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J Neurovirol. 2009;1-18
122. Levine AJ, Reynolds S, Cox C, et al; the Mutlicenter AIDS Cohort Study. Longitudinal analysis of interactive effects of host genotype, stimulant use, and HIV status upon neurocognitive functioning. 11th Symposium of the International Society on NeuroVirology; May 29- June 2, 2012; New York, NY.
123. Aouizerat BE, Pearce CL, Miaskowski C. The search for host genetic factors of HIV/AIDS pathogenesis in the post-genome era: Progress to date and new avenues for discovery. Curr HIV/AIDS Rep. 2011;8:38-44
124. An P, Winkler CA. Host genes associated with HIV/AIDS: Advances in gene discovery. Trends Genet. 2010;26:119-131
125. Belbin O, Carrasquillo MM, Crump M, et al. Investigation of 15 of the top candidate genes for late-onset Alzheimeŕs disease. Hum Genet. 2011;129:273-282
126. Seshadri S, Fitzpatrick AL, Ikram MA, et al. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA. 2010;303:1832- 1840
127. Laumet G, Chouraki V, Grenier-Boley B, et al. Systematic analysis of candidate genes for Alzheimeŕs disease in a French, genome-wide association study. J Alzheimers Dis. 2010;20:1181-1188
128. Braskie MN, Jahanshad N, Stein JL, et al. Common Alzheimeŕs disease risk variant within the CLU gene affects white matter microstructure in young adults. J Neurosci. 2011;31:6764-6770
129. Ho AJ, Stein JL, Hua X, et al. A commonly carried allele of the obesityrelated FTO gene is associated with reduced brain volume in the healthy elderly. Proc Natl Acad Sci U S A 2010;107:8404-8409
130. Noorbakhsh F, Ramachandran R, Barsby N, et al. MicroRNA profiling reveals new aspects of HIV neurodegeneration: Caspase-6 regulates astrocyte survival. FASEB J. 2010;24:1799-1812
131. Gelman BB, Soukup VM, Schuenke KW, et al. Acquired neuronal channelopathies in HIV-associated dementia. J Neuroimmunol. 2004; 157:111-119
132. Benos DJ, Hahn BH, Bubien JK, et al. Envelope glycoprotein gp120 of human immunodeficiency virus type 1 alters ion transport in astrocytes: Implications for AIDS dementia complex. Proc Natl Acad Sci U S A 1994;91:494-498
133. Cantor RM, Lange K, Sinsheimer JS. Prioritizing GWAS results: A review of statistical methods and recommendations for their application. Am J Hum Genet. 2010;86:6-22
134. Shapshak P, Duncan R, Torres-Munoz JE, et al. Analytic approaches to differential gene expression in AIDS versus control brains. Front Biosci. 2004;9:2935-2946
135. Presson AP, Sobel EM, Papp JC, et al. Integrated weighted gene coexpression network analysis with an application to chronic fatigue syndrome. BMC Syst Biol. 2008;2:95
136. Giri MS, Nebozhyn M, Showe L, et al. Microarray data on gene modulation by HIV-1 in immune cells: 2000-2 J Leukoc Biol. 2006;80: 1031-1043
137. Kim SY, Li J, Bentsman G, et al. Microarray analysis of changes in cellular gene expression induced by productive infection of primary human astrocytes: Implications for HAD. J Neuroimmunol. 2004;157: 17-26
138. Kolson DL, Sabnekar P, Baybis M, et al. Gene expression in TUNELpositive neurons in human immunodeficiency virus-infected brain. J Neurovirol. 2004;10(suppl 1):102-107
139. Borjabad A, Brooks AI, Volsky DJ. Gene expression profiles of HIV-1- infected glia and brain: Toward better understanding of the role of astrocytes in HIV-1-associated neurocognitive disorders. J Neuroimmune Pharmacol. 5:44-62
140. Masliah E, Roberts ES, Langford D, et al. Patterns of gene dysregulation in the frontal cortex of patients with HIV encephalitis. J Neuroimmunol. 2004;157:163-175
141. Salaria S, Badkoobehi H, Rockenstein E, et al. Toll-like receptor pathway gene expression is associated with human immunodeficiency virusassociated neurodegeneration. J Neurovirol. 2007;13:496-503
142. Everall I, Salaria S, Roberts E, et al. Methamphetamine stimulates interferon inducible genes in HIV infected brain. J Neuroimmunol. 2005;170:158-171
143. Winkler JM, Chaudhuri AD, Fox HS. Translating the brain transcriptome in neuroAIDS: From non-human primates to humans. J Neuroimmune Pharmacol. 2012
144. Roberts ES, Zandonatti MA, Watry DD, et al. Induction of pathogenic sets of genes in macrophages and neurons in Neuro AIDS. Am J Pathol. 2003;162:2041-2057
145. Gersten M, Alirezaei M, Marcondes MC, et al. An integrated systems analysis implicates EGR1 downregulation in simian immunodeficiency virus encephalitis-induced neural dysfunction. J Neurosci. 2009;29: 12467-12476
146. Gelman BB, Chen T, Lisinicchia JG, et al. The National NeuroAIDS Tissue Consortium brain gene array: Two types of HIV-associated neurocognitive impairment. PLoS One. 2012;7:e46178
147. Levine AJ, Miller JA, Shapshak P, et al. Systems analysis of human brain gene expression: Mechanisms for HIV-associated neurocognitive impairment and common pathways with Alzheimeŕs disease. BMC Med Genomics. 2013;6:4
148. Langfelder P, Horvath S. WGCNA: An R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559
149. Oldham MC, Konopka G, Iwamoto K, et al. Functional organization of the transcriptome in human brain. Nat Neurosci. 2008;11:1271-1282
150. Blalock EM, Geddes JW, Chen KC, et al. Incipient Alzheimeŕs disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA. 2004;101:2173-2178
151. Borjabad A, Volsky DJ. Common transcriptional signatures in brain tissue from patients with HIV-associated neurocognitive disorders, Alzheimeŕs disease, and multiple sclerosis. J Neuroimmune Pharmacol. 2012
152. Borjabad A, Morgello S, Chao W, et al. Significant effects of antiretroviral therapy on global gene expression in brain tissues of patients with HIV-1-associated neurocognitive disorders. PLoS Pathog. 2011;7: E1002213
153. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol. 2008;65:65-70
154. Marra CM, Zhao Y, Clifford DB, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS. 2009;23:1359-1366
155. Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: Prevalence and risk factors. J Acquir Immune Defic Syndr. 2007;45:174-182
156. Cysique LA, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology. 2009;73:342-348
157. Marra CM, Lockhart D, Zunt JR, et al. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology. 2003;60:1388-1390
158. Garvey L, Winston A, Walsh J, et al. Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology. 2011;76:693-700
159. Kahouadji Y, Dumurgier J, Sellier P, et al. Cognitive function after several years of antiretroviral therapy with stable central nervous system penetration score. HIV Med. 2012
160. Pulliam L, Gascon R, Stubblebine M, et al. Unique monocyte subset in patients with AIDS dementia. Lancet. 1997;349:692-695
161. Ellery PJ, Tippett E, Chiu YL, et al. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol. 2007;178:6581-6589
162. Peluso R, Haase A, Stowring L, et al. A Trojan Horse mechanism for the spread of visna virus in monocytes. Virology. 1985;147:231-236
163. Ancuta P, Moses A, Gabuzda D. Transendothelial migration of CD16+ monocytes in response to fractalkine under constitutive and inflammatory conditions. Immunobiology. 2004;209:11-20
164. Kraft-Terry SD, Buch SJ, Fox HS, et al. A coat of many colors: Neuroimmune crosstalk in human immunodeficiency virus infection. Neuron. 2009;64:133-145
165. Persidsky Y, Ghorpade A, Rasmussen J, et al. Microglial and astrocyte chemokines regulate monocyte migration through the blood-brain barrier in human immunodeficiency virus-1 encephalitis. Am J Pathol. 1999;155:1599-1611
166. Persidsky Y, Zheng J, Miller D, et al. Mononuclear phagocytes mediate blood-brain barrier compromise and neuronal injury during HIV-1- associated dementia. J Leukoc Biol. 2000;68:413-422
167. Cosenza MA, Zhao ML, Si Q, et al. Human brain parenchymal microglia express CD14 and CD45 and are productively infected by HIV-1 in HIV-1 encephalitis. Brain Pathol. 2002;12:442-455
168. Kedzierska K, Crowe SM. The role of monocytes and macrophages in the pathogenesis of HIV-1 infection. Curr Med Chem. 2002;9:1893-1903
169. Glass JD, Fedor H, Wesselingh SL, et al. Immunocytochemical quantitation
170. Adle-Biassette H, Chretien F, Wingertsmann L, et al. Neuronal apoptosis does not correlate with dementia in HIV infection but is related to microglial activation and axonal damage. Neuropathol Appl Neurobiol. 1999;25:123-133
171. Lindl KA, Akay C, Wang Y, et al. Expression of the endoplasmic reticulum stress response marker, BiP, in the central nervous system of HIV-positive individuals. Neuropathol Appl Neurobiol. 2007;33: 658-669
172. Kaul M, Lipton SA. Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr HIV Res. 2006;4:307-318
173. Buckner CM, Calderon TM, Willams DW, et al. Characterization of monocyte maturation/differentiation that facilitates their transmigration across the blood-brain barrier and infection by HIV: Implications for Neuro AIDS. Cell Immunol. 2011;267:109-123
174. Pulliam L, Sun B, Rempel H. Invasive chronic inflammatory monocyte phenotype in subjects with high HIV-1 viral load. J Neuroimmunol. 2004;157:93-98
175. Pulliam L, Rempel H, Sun B, et al. A peripheral monocyte interferon phenotype in HIV infection correlates with a decrease in magnetic resonance spectroscopy metabolite concentrations. AIDS. 2011;25: 1721-1726
176. Levine AJ, Horvath S, Miller EN, et al. Transcriptome analysis of HIVinfected peripheral blood monocytes: Gene transcripts and networks associated with neurocognitive functioning. J Neuroimmunol. 2013
177. Horvath S, Zhang B, Carlson M, et al. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci U S A 2006;103:17402-17407
178. Yoshioka M, Shapshak P, Srivastava AK, et al. Expression of HIV-1 and interleukin-6 in lumbosacral dorsal root ganglia of patients with AIDS. Neurology. 1994;44:1120-1130
179. Pedersen KK, Pedersen M, Gaardbo JC, et al. Persisting inflammation and chronic immune activation but intact cognitive function in HIVinfected patients after long term treatment with combination antiretroviral therapy. J Acquir Immune Defic Syndr. 2013
180. Perez DI, Gil C, Martinez A. Protein kinases CK1 and CK2 as new targets for neurodegenerative diseases. Med Res Rev. 2011;31:924-954
181. Janeczko K. The proliferative response of S-100 protein-positive glial cells to injury in the neonatal rat brain. Brain Res. 1991;564:86-90
182. Kuwabara K, Matsumoto M, Ikeda J, et al. Purification and characterization of a novel stress protein, the 150-kDa oxygen-regulated protein (ORP150), from cultured rat astrocytes and its expression in ischemic mouse brain. J Biol Chem. 1996;271:5025-5032
183. Ozawa K, Kondo T, Hori O, et al. Expression of the oxygen-regulated protein ORP150 accelerates wound healing by modulating intracellular VEGF transport. J Clin Invest. 2001;108:41-50
184. Tamatani M, Matsuyama T, Yamaguchi A, et al. ORP150 protects against hypoxia/ischemia-induced neuronal death. Nat Med. 2001;7: 317-323
185. Zhao L, Rosales C, Seburn K, et al. Alteration of the unfolded protein response modifies neurodegeneration in a mouse model of Marinesco- Sjogren syndrome. Hum Mol Genet. 2010;19:25-35
186. Kounnas MZ, Moir RD, Rebeck GW, et al. LDL receptor-related protein, a multifunctional ApoE receptor, binds secreted beta-amyloid precursor protein and mediates its degradation. Cell 1995;82:331-340
187. Liu Y, Jones M, Hingtgen CM, et al. Uptake of HIV-1 tat protein mediated by low-density lipoprotein receptor-related protein disrupts the neuronal metabolic balance of the receptor ligands. Nat Med. 2000;6:1380-1387
188. Kang DE, Saitoh T, Chen X, et al. Genetic association of the lowdensity lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimeŕs disease. Neurology. 1997; 49:56-61
189. Bian L, Yang JD, Guo TW, et al. Association study of the A2M and LRP1 Genes with Alzheimer disease in the Han Chinese. Biol Psychiatry. 2005;58:731-737
190. Itoh K, Wakabayashi N, Katoh Y, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev. 1999;13:76-86
191. Motohashi H, Yamamoto M. Nrf2-Keap1 defines a physiologically important stress response mechanism. Trends Mol Med. 2004;10:549-557
192. Tanji K, Maruyama A, Odagiri S, et al. Keap1 is localized in neuronal and glial cytoplasmic inclusions in various neurodegenerative diseases. J Neuropathol Exp Neurol. 2013;72:18-28
193. Zhao J, Redell JB, Moore AN, et al. A novel strategy to activate cytoprotective genes in the injured brain. Biochem Biophys Res Commun. 2011;407:501-506
194. Reddy PV, Agudelo M, Atluri VS, et al. Inhibition of nuclear factor erythroid 2-related factor 2 exacerbates HIV-1 gp120-induced oxidative and inflammatory response: Role in HIV associated neurocognitive disorder. Neurochem Res. 2012;37:1697-1706
195. Lo SC, Li X, Henzl MT, et al. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling. EMBO J. 2006;25: 3605-3617
196. Surh YJ, Kundu JK, Na HK. Nrf2 as a master redox switch in turning on the cellular signaling involved in the induction of cytoprotective genes by some chemopreventive phytochemicals. Planta Med. 2008; 74:1526-1539
197. Letendre SL, Woods SP, Ellis RJ, et al. Lithium improves HIVassociated neurocognitive impairment. AIDS. 2006;20:1885-1888
198. Guo L, Xing Y, Pan R, et al. Curcumin protects microglia and primary rat cortical neurons against HIV-1 gp120-mediated inflammation and apoptosis. PLoS One. 2013;8:e70565
199. Roberts ES, Burudi EM, Flynn C, et al. Acute SIV infection of the brain leads to upregulation of IL6 and interferon-regulated genes: Expression patterns throughout disease progression and impact on neuro AIDS. J Neuroimmunol. 2004;157:81-92
200. Shapshak P, Duncan R, Minagar A, et al. Elevated expression of IFNgamma in the HIV-1 infected brain. Front Biosci. 2004;9:1073-1081
201. Eletto D, Russo G, Passiatore G, et al. Inhibition of SNAP25 expression by HIV-1 Tat involves the activity of mir-128a. J Cell Physiol. 2008; 216:764-770
202. Yelamanchili SV, Chaudhuri AD, Chen LN, et al. MicroRNA-21 dysregulates the expression of MEF2C in neurons in monkey and human SIV/HIV neurological disease. Cell Death Dis. 2010;1:e77
203. Tatro ET, Scott ER, Nguyen TB, et al. Evidence for Alteration of Gene Regulatory Networks through Micro RNAs of the HIV-infected brain: Novel analysis of retrospective cases. PLoS One. 2010;5:e10337
204. Mukerjee R, Chang JR, Del Valle L, et al. Deregulation of micro RNAs by HIV-1 Vpr protein leads to the development of neurocognitive disorders. J Biol Chem. 2011;286:34976-34985
205. Sun JM, Spencer VA, Chen HY, et al. Measurement of histone acetyltransferase and histone deacetylase activities and kinetics of histone acetylation. Methods. 2003;31:12-23
206. Thomas EA. Focal nature of neurological disorders necessitates isotypeselective histone deacetylase (HDAC) inhibitors. Mol Neurobiol. 2009; 40:33-45
207. Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov. 2008;7:854-868
208. Saiyed ZM, Gandhi N, Agudelo M, et al. HIV-1 Tat upregulates expression of histone deacetylase-2 (HDAC2) in human neurons: Implication for HIV-associated neurocognitive disorder (HAND). Neurochem Int. 2011;58:656-664
209. Perez-Santiago J, PN, Letendre S, et al. DNA methylation correlates with neurological decline in HIV-infected individuals. 19th Conference on Retroviruses and Opportunistic Infections. Seattle, Washington; 2012
210. Persidsky Y, Gendelman HE. Mononuclear phagocyte immunity and the neuropathogenesis of HIV-1 infection. J Leukoc Biol. 2003;74:691-701
211. Thompson PM, Dutton RA, Hayashi KM, et al. 3D mapping of ventricular and corpus callosum abnormalities in HIV/AIDS. Neuroimage. 2006;31:12-23
212. Chiang MC, Dutton RA, Hayashi KM, et al. 3D pattern of brain atrophy in HIV/AIDS visualized using tensor-based morphometry. Neuroimage. 2007;34:44-60
213. Thompson PM, Dutton RA, Hayashi KM, et al. Thinning of the cerebral cortex visualized in HIV/AIDS reflects CD4+ T lymphocyte decline. Proc Natl Acad Sci U S A 2005;102:15647-15652
214. Chang L, Lee PL, Yiannoutsos CT, et al. A multicenter in vivo proton- MRS study of HIV-associated dementia and its relationship to age. Neuroimage. 2004;23:1336-1347
215. Ances BM, Roc AC, Wang J, et al. Caudate blood flow and volume are reduced in HIV+ neurocognitively impaired patients. Neurology. 2006; 66:862-866
216. Schifitto G, Zhong J, Gill D, et al. Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol. 2009;15:176-186
217. Masliah E, Heaton RK, Marcotte TD, et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. HNRC Group. The HIV Neurobehavioral Research Center. Ann Neurol. 1997;42:963-972
218. Achim CL, Adame A, Dumaop W, et al. Increased accumulation of intraneuronal amyloid beta in HIV-infected patients. J Neuroimmune Pharmacol. 2009;4:190-199
219. Rempel HC, Pulliam L. HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS. 2005;19:127-135
220. Green DA, Masliah E, Vinters HV, et al. Brain deposition of betaamyloid is a common pathologic feature in HIV positive patients. AIDS. 2005;19:407-411
221. Esiri MM, Biddolph SC, Morris CS. Prevalence of Alzheimer plaques in AIDS. J Neurol Neurosurg Psychiatry. 1998;65:29-33
222. Garden GA. Microglia in human immunodeficiency virus-associated neurodegeneration. Glia. 2002;40:240-251
223. Bell JE, Brettle RP, Chiswick A, et al. HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Brain. 1998;121(pt 11):2043-2052
224. Everall IP, Hansen LA, Masliah E. The shifting patterns of HIV encephalitis neuropathology. Neurotox Res. 2005;8:51-61
225. Boven LA, Middel J, Breij EC, et al. Interactions between HIV-infected monocyte-derived macrophages and human brain microvascular endothelial cells result in increased expression of CC chemokines. J Neurovirol. 2000;6:382-389
226. Mortimer JA, Snowdon DA, Markesbery WR. The effect of APOEepsilon4 on dementia is mediated by Alzheimer neuropathology. Alzheimer Dis Assoc Disord. 2009;23:152-157
227. Bennett DA, Schneider JA, Wilson RS, et al. Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. J Neurol Neurosurg Psychiatry. 2005;76:1194-1199
228. Shulman JM, Chibnik LB, Aubin C, et al. Intermediate phenotypes identify divergent pathways to Alzheimeŕs disease. PLoS One. 5: E11244
229. Bennett DA, De Jager PL, Leurgans SE, et al. Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles. Neurology. 2009;72:1495-1503
230. Barabasi AL, Oltvai ZN. Network biology: Understanding the celĺs functional organization. Nat Rev Genet. 2004;5:101-113
231. Voineagu I, Wang X, Johnston P, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature. 2011;474:380-384
232. Horvath S, Zhang Y, Langfelder P, et al. Aging effects on DNA methylation modules in human brain and blood tissue. Genome Biol. 2012; 13:R97
233. Langfelder P, Mischel PS, Horvath S. When is hub gene selection better than standard meta-analysis PLoS One. 2013;8:e61505
234. Holzinger ER, Hulgan T, Ellis RJ, et al. Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J Neurovirol. 2012;18:511-520
235. Canter JA, Haas DW, Kallianpur AR, et al. The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy. Pharmacogenomics J. 2008; 8:71-77
236. Kamerman PR, Wadley AL, Cherry CL. HIV-associated sensory neuropathy: Risk factors and genetics. Curr Pain Headache Rep. 2012;16: 226-236